Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
Portfolio Pulse from
Lisata Therapeutics has completed enrollment in its Phase 1b/2a CENDIFOX trial, which tests the combination of certepetide with neoadjuvant FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.
December 10, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lisata Therapeutics has completed enrollment in its CENDIFOX trial, a significant milestone in testing certepetide with FOLFIRINOX-based therapies for certain cancers.
The completion of enrollment in the CENDIFOX trial is a critical step for Lisata Therapeutics, indicating progress in their clinical research. This could positively impact investor sentiment and the stock price as it shows advancement in their pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100